ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Play 10min Summary ArriVent BioPharma's lead molecule, firmonertinib, targets NSCLC with EGFR Exon 20 insertion mutations and shows potential in both classical and nonstandard EGFR mutations. Firmonertinib has demonstrated superior efficacy over first-generation TKIs and can cross the blood-brain barrier, showing promise for patients with brain metastases. With a market cap of $798mn and a cash balance sufficient for over 10 quarters, ArriVent is financially stable to continue its development. Upcoming catalysts include topline data from the phase 3 FURVENT trial in 2025, making firmonertinib a molecule worth watching in the nonstandard EGFRm space. koto_feja ArriVent BioPharma, Inc. ( NASDAQ: AVBP ) is a recent IPO which is bringing a molecule known as firmonertinib, originally developed in China, to patients in the United States and globally. The lead indication is NSCLC with EGFR Exon 20 insertion mutation, where it has a phase 3 t
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at Citigroup Inc. from $30.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $39.00 price target on the stock, up previously from $35.00.MarketBeat
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $30.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer [Yahoo! Finance]Yahoo! Finance
AVBP
Earnings
- 8/14/24 - In-Line
AVBP
Sec Filings
- 9/9/24 - Form 8-K
- 8/14/24 - Form 10-Q
- 8/14/24 - Form 8-K
- AVBP's page on the SEC website